Self-urinary Infection Testing Market Snapshot (2023 to 2033)
According to Future Market Insights, the market for self-urinary infection testing is likely to project a compounded annual growth rate (CAGR) of 7.8% during the assessment period ranging from 2023 to 2033. As of 2023, a valuation of US$ 8.9 billion has been estimated for the market. This will eventually rise to US$ 18.86 billion in 2033. Growth is expected to be fuelled by a rising prevalence of uncomplicated urinary tract infections and the subsequent need for self-testing kits, given their convenience and cost-effectiveness.
Urinary tract infections (UTIs) are the most common bacterial infection in the world, accounting for nearly 25% of all infections in women, and resulting in 250 million infections annually. Almost half of all women with a UTI will experience recurrent infections requiring additional antibiotic treatment. One out of three women will have to get antibiotic treatment for UTIs by the age of 24. The key culprit in this increase is an overdose of antibiotics in medicine and livestock.
As per a study conducted in 2019, incident cases of UTI, urolithiasis, and benign prostatic hyperplasia (BPH) increased by 60.48%, 48.57%, and 105.7% respectively from 1990. While the burden of urolithiasis and BPH has reduced considerably, UTI continues to pose a significant health risk to patients. Consequently, numerous therapeutic and treatment approaches have been developed in recent years. One of these approaches includes the detection of the disease before its progression, rendering the need for self-testing kits a necessity.
Timely and accurate identification and determination of the antimicrobial susceptibility of uropathogens is central to the management of UTIs. While urine dipsticks are amenable to point-of-care testing, they do not have adequate accuracy or provide a microbiological diagnosis. Likewise, urine culture with antimicrobial susceptibility testing takes 2-3 days for results to be declared, and requires a laboratory setting. The use of antibiotics has led to an increase in multidrug-resistant organisms, thus ruling out its usage. Through the method of elimination, self-testing kits have emerged as the most convenient solution.
Self-urinary infection testing providers are leveraging technological advancements to the fullest in order to introduce top-of-the-line products. French consumer electronics company Withings introduced the U-Scan, a hockey-puck-shaped device that can be installed inside toilet bowls to analyse urine composition at the Consumer Electronics Show 2023, organized in January. The company is initially releasing three cartridges. One is for women who want to track their menstrual cycles; the second provides more general health markers, such as fluid balance, protein-vegetable balance, and Vitamin C levels.
Inside the U-Scan is a replaceable cartridge, good for about three months, filled with dozens of test pods into which urine is injected. Chemical reactions then occur when one or several biomarkers are detected, producing specific colors that are analysed by an optical sensor. The results of the U-Scan’s tests are shared over Wi-Fi to Withings’ private servers and made available through the company’s accompanying mobile apps, which allows the results and each user’s personal health data to be tracked over time.
Similarly, HealthyMe offers a urinary tract infection test kit comprising 3 individually-wrapped strips. The test is highly effective, providing results in just 2 minutes. The testing kit determines the presence of leukocytes and nitrites in urine. The future landscape is expected to be highly opportunistic, with many such product launches slated in the years to come.
Expected Market Value of Self-urinary Infection Testing in 2023
US$ 8.9 billion
Projected Market Value of Self-urinary Infection Testing in 2033
US$ 18.86 billion
Global Growth Rate (2023 to 2033)
CAGR of 7.8%
Self-urinary Infection Testing Market Overview
According to the latest research by Future Market Insights, Self-urinary infection testing market is set to witness a 7.8% growth during the year 2021 to 2031. The market is expected to witness growth owing to increasing prevalence of urinary tract infections and kidney diseases, surging volume of patients suffering from nephropathic disorders across the globe, increasing prevalence of geriatric population, changing lifestyle of the people.
What is Driving Demand for Self-urinary Infection Testing?
A major factor boosting the growth of the market is the increasing prevalence of UTIs and nephropathic disorders. The lifestyle diseases like hypertension, diabetes, and obesity have an adverse effect on the excretion system, which includes the urinary tract, kidneys, lungs, skin and bladder. It affects the content of urine, appearance, and the concentration, hence leading to different nephropathic disorders.
Moreover, rise in the healthcare expenditure by the government initiatives promotes the affordability of devices, leading to growth sales of urinalysis products, boosting the growth of the market.
Furthermore, technological advancements in the field of self-diagnostics which is expected to boost the development of the market. For instance, in 2019, the federal FDA (Food and Drug Administration) approved a smartphone-based home urine test which allows patients with high-risk pregnancies, chronic diseases or urinary tract infections to observe their health by means of a testing method which is as easy as taking a smartphone selfie.
Increasing Number of UTIs (Urinary Tract Infections) and Nephropathic Disorders Likely to Boost Self-urinary Infection Testing Sales
Self-urinary infection testing industry growth is projected to accelerate in the next five years, boosted by increasing prevalence of UTIs and nephropathic disorders which creates higher demand for different types of urine tests. The rising prevalence of UTIs and nephropathic diseases are caused by lifestyle diseases such as diabetes, hypertension, and obesity which makes an adverse effect on the excretion system, including bladder, urinary tract, and kidney.
A urinary screening program is suggested as an essential element for reducing the incidence of UTIs and kidney diseases which is anticipated to drive the demand for urinalysis test and boost the growth of Self-urinary infection testing market.
USA and Canada Self-urinary Infection Testing Market Outlook
The USA Self-urinary infection testing market is expected to observe a robust growth in the market owing to high adoption of urinalysis for treatment of the urinary tract infections and liver disease, growth in research activities in the field of urinalysis and rising awareness among the people about urinalysis.
As per the National Diabetes Statics Report in 2017, approximately 30.3 million Americans (nearly 1 in 10) are affected with diabetes. Moreover, rising government initiatives for growing awareness of urinalysis among the people is a key factor boosting the market.
Europe Demand Outlook for Self-urinary Infection Testing
Europe would witness the highest growth after North America because of the rising prevalence of kidney diseases, rising per capita income resulting to better standard of living, rising healthcare spending, increasing demand for improved quality medical care, and rising awareness regarding urinalysis tests in Europe.
In addition, the rise in the incidence of nephropathic disorders and UTIs leads to the increasing demand for the diagnostic system, particularly self-diagnostic, because it is the most rapid growing segment of the diagnostic systems.
Who are the Key Manufacturers and Suppliers of Self-urinary Infection Testing?
Some of the leading manufacturers and suppliers of Self-urinary infection testing include
- Cardinal Health.
- Siemens Healthcare Private Limited
- F. Hoffmann-La Roche Ltd
- Beckman Coulter, Inc.
- Sysmex Middle East FZ-LLC
- Quidel Corporation.
- Bio-Rad Laboratories, Inc.
- ARKRAY, Inc.
- ACON Laboratories, Inc.
- 77 Elektronika Kft
- URIT MEDICAL ELECTRONIC Co., LTD.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Healthy.io Ltd
- Q Bio, Inc.
- Scanwell Health, Inc.
- Nova Biomedical
- bioMérieux SA
The global Self-urinary infection testing market is slightly fragmented over the forecast years because of the presence of numerous testing device manufacturers who offer devices such as urinalysis test consumables and systems. Different Self-urinary infection testing device manufacturers are concentrated on developing novel technologies like dipsticks, recently approved mobile based home urine test.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
- Urine Assay Kit
- Creatinine Urine Diagnostic Test Kit
- Home Protein Urine Test Strips
- Kidney Diseases
- Urinary Tract Infections
- Other Diseases
By End User:
- Diagnostic Laboratories
- Hospitals & Clinics
- Home Care Settings
- Assisted Living Healthcare Facilities
- Research Laboratories & Institutes
- North America
- Latin America
- South Asia
- East Asia
- Middle East & Africa